dalcetrapib
Reduction of recurrent myocardial infarction in post-acute coronary syndrome (ACS) patients with ADCY9 AA genotype
Key Facts
About DalCor Pharmaceuticals
DalCor Pharmaceuticals is a clinical-stage biotech developing dalcetrapib, a precision cardiovascular drug for post-heart attack patients with the ADCY9 AA genotype, representing approximately 20% of the global population. The company is advancing the drug into the Dal-GenE-2 (DAL-302) Phase 3 confirmatory trial based on promising Phase 3 data from the dal-GenE study, which showed a significant reduction in myocardial infarction risk. DalCor holds an exclusive worldwide license for dalcetrapib and its associated genetic marker, and has partnered with Roche on a companion diagnostic. The company is led by an experienced management team with deep cardiovascular and pharmaceutical industry expertise.
View full company profile